Jack Higgins is a prominent inventor based in Georgetown, TX (US), known for his significant contributions to the field of therapeutic molecules. With a total of 8 patents to his name, Higgins has made remarkable strides in developing innovative solutions for treating various diseases, including cancer and immune disorders.

Latest Patents

Higgins' latest patents include a multivalent CD20-binding molecule comprising Shiga toxin A subunit effector polypeptides. This invention provides multivalent CD20-binding molecules and compositions for the selective killing of specific cell types and as therapeutics for a variety of diseases. These molecules can deliver agents into CD20-expressing cells, collect diagnostic information, and monitor the treatment of diseases such as cancers and immune disorders. Another notable patent involves HER2-targeting molecules comprising de-immunized Shiga toxin A subunit scaffolds. These molecules exhibit reduced immunogenic potential while retaining potent cytotoxicity, making them suitable for selectively killing HER2 positive tumor cells and delivering therapeutic agents.

Career Highlights

Higgins is currently associated with Molecular Templates, Inc., where he continues to push the boundaries of innovation in therapeutic development. His work has been instrumental in advancing the understanding and application of targeted therapies in oncology.

Collaborations

Higgins collaborates with notable colleagues, including Eric Poma and Erin Willert, who contribute to the innovative environment at Molecular Templates, Inc. Their combined expertise fosters a culture of creativity and scientific advancement.

Conclusion

Jack Higgins stands out as a leading inventor in the field of therapeutic molecules, with a focus on innovative solutions for complex medical challenges. His contributions are paving the way for new treatments that could significantly impact patient care and outcomes.

This text is generated by artificial intelligence and may not be accurate.